Latest news with #Smith&Nephew
Time of India
08-05-2025
- Health
- Time of India
CORI Robotic Partial Knee Replacement performed on 57 year old female patient in Mangaluru
1 2 MANGALURU : AJ Hospital and Research Centre, has successfully performed CORI Robotic Unicondylar Knee Replacement (UKR). The breakthrough procedure was carried out by Dr. Mayur Rai, Senior Consultant Orthopaedic Surgeon , and Dr. Mohammed Shabir Kassim , Consultant Orthopaedic and Arthroscopic Surgeon. The CORI robotic surgical system represents the latest in orthopaedic innovation, providing real-time, 3D digital modelling and precision-guided instrumentation. This allows surgeons to perform knee replacements with unmatched accuracy, resulting in better outcomes, faster recovery, and improved long-term function. Unicondylar Knee Replacement, commonly known as partial knee replacement, is a minimally invasive procedure designed for patients with damage confined to one compartment of the knee. The use of the CORI robotic platform enhances surgical precision, ensures personalised implant placement, and preserves more of the patient's natural anatomy. Dr. Mayur Rai said, 'The introduction of CORI robotic technology in Mangaluru is a leap forward in joint replacement surgery. It allows us to deliver consistently accurate and personalised care with superior functional outcomes.' Dr. Mohammed Shabir Kassim said, 'This technology-driven approach reduces pain, minimises tissue damage, and allows patients to walk within hours and return to daily activities much sooner than traditional methods.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 10 Mysterious Photos That Cannot Be Explained True Edition Undo The patient who underwent the procedure is recovering well and already began post-operative physiotherapy. Dr. Prashanth Marla K , Medical Director of AJ Hospital & Research Centre, said our collaboration with Smith & Nephew and the adoption of the CORI robotic platform reflects our dedication to providing world-class orthopaedic care in coastal Karnataka. This is a proud moment for the entire team and a major step forward in patient-centric, precision-driven healthcare. This is the only robotic system wherein we can do complete knee, partial knee, and hip replacements.
Yahoo
08-04-2025
- Business
- Yahoo
Are Poor Financial Prospects Dragging Down Smith & Nephew plc (LON:SN. Stock?
With its stock down 15% over the past month, it is easy to disregard Smith & Nephew (LON:SN.). Given that stock prices are usually driven by a company's fundamentals over the long term, which in this case look pretty weak, we decided to study the company's key financial indicators. Particularly, we will be paying attention to Smith & Nephew's ROE today. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In simpler terms, it measures the profitability of a company in relation to shareholder's equity. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. The formula for ROE is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Smith & Nephew is: 7.8% = US$412m ÷ US$5.3b (Based on the trailing twelve months to December 2024). The 'return' is the profit over the last twelve months. Another way to think of that is that for every £1 worth of equity, the company was able to earn £0.08 in profit. Check out our latest analysis for Smith & Nephew Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features. When you first look at it, Smith & Nephew's ROE doesn't look that attractive. Yet, a closer study shows that the company's ROE is similar to the industry average of 6.8%. But Smith & Nephew saw a five year net income decline of 13% over the past five years. Bear in mind, the company does have a slightly low ROE. So that's what might be causing earnings growth to shrink. That being said, we compared Smith & Nephew's performance with the industry and were concerned when we found that while the company has shrunk its earnings, the industry has grown its earnings at a rate of 3.8% in the same 5-year period. Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. Doing so will help them establish if the stock's future looks promising or ominous. Is SN. fairly valued? This infographic on the company's intrinsic value has everything you need to know. Smith & Nephew's high three-year median payout ratio of 107% suggests that the company is depleting its resources to keep up its dividend payments, and this shows in its shrinking earnings. Paying a dividend higher than reported profits is not a sustainable move. Our risks dashboard should have the 2 risks we have identified for Smith & Nephew. In addition, Smith & Nephew has been paying dividends over a period of at least ten years suggesting that keeping up dividend payments is way more important to the management even if it comes at the cost of business growth. Existing analyst estimates suggest that the company's future payout ratio is expected to drop to 40% over the next three years. Accordingly, the expected drop in the payout ratio explains the expected increase in the company's ROE to 17%, over the same period. On the whole, Smith & Nephew's performance is quite a big let-down. Particularly, its ROE is a huge disappointment, not to mention its lack of proper reinvestment into the business. As a result its earnings growth has also been quite disappointing. With that said, we studied the latest analyst forecasts and found that while the company has shrunk its earnings in the past, analysts expect its earnings to grow in the future. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
12-03-2025
- Business
- Yahoo
Smith & Nephew Full Year 2024 Earnings: EPS Misses Expectations
Revenue: US$5.81b (up 4.7% from FY 2023). Net income: US$412.0m (up 57% from FY 2023). Profit margin: 7.1% (up from 4.7% in FY 2023). EPS: US$0.47 (up from US$0.30 in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.7%. The primary driver behind last 12 months revenue was the Orthopaedics segment contributing a total revenue of US$2.31b (40% of total revenue). The largest operating expense was General & Administrative costs, amounting to US$2.90b (79% of total expenses). Explore how SN.'s revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in the United Kingdom. Performance of the British Medical Equipment industry. The company's shares are down 3.1% from a week ago. What about risks? Every company has them, and we've spotted 2 warning signs for Smith & Nephew you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
06-03-2025
- Business
- Yahoo
Smith & Nephew opens door to break-up in response to activist, The Times says
Smith & Nephew has opened up to a possible break-up of the company amid activist pressure to consider a separation of its largest segment, its struggling orthopedics division, marking a shift in the company's public position, reported The Times' Alex Ralph. In a meeting with City analysts after Smith & Nephew's full-year results last week, CFO John Rogers said the group remained committed to the turnaround of the largest of the group's three units, but could consider options if its growth does not 'sustainably improve' or does not result in a re-rating in the shares, The Times noted. See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and streamline your search for investment opportunities with TipRanks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on SNN: Smith & Nephew announces its efforts to develop technology in Spatial Surgery Smith & Nephew price target raised to 1,300 GBp from 1,250 GBp at Deutsche Bank Smith & Nephew Announces Share Capital Details Positive Outlook for Smith & Nephew: Buy Rating Driven by Strategic Initiatives and Market Growth Potential Smith & Nephew Snats (SNN) Announces Q2 Dividend: Read On for Important Dates Sign in to access your portfolio
The Independent
25-02-2025
- Business
- The Independent
Banks and defence stocks help lift FTSE 100 after Starmer ups security spending
Banking stocks and weapons-maker BAE Systems helped lift London's FTSE 100 higher on Tuesday, as the Prime Minister announced the biggest hike to defence spending since the end of the Cold War. The blue-chip index gained 9.69 points, or 0.11%, to close at 8,668.67. Lloyds, HSBC and NatWest were all climbing with gains of about 2%, while BAE Systems rose 3% following Sir Keir Starmer's speech. The plan to slash the current aid budget will see defence spending rise from the current 2.3% share of the economy to 2.5% from 2027. It comes three years after Russia's full-scale invasion of Ukraine, and amid uncertainty over US President Donald Trump's commitment to European security. Sir Keir will travel to Washington later this week for talks with the US president, who has repeatedly pushed for Europe to increase its defence spending. A weaker session for mining stocks hit the FTSE 100 on Tuesday as oil prices fell sharply. The price of Brent crude oil was down about 2.2% to 74.10 US dollars per barrel. In Paris, the Cac 40 was down 0.49%, and in Frankfurt, the Dax moved 0.13% lower. Over in New York, the S&P 500 was down about 0.8%, and the Dow Jones was more or less flat by the time European markets closed. The pound was rising 0.25% against the US dollar, at 1.266, but down 0.1% against the euro, at 1.205. In company news, Smith & Nephew rose to the top of the FTSE 100 after the medical technology firm reported a recovery in sales in the US. The company, which has business lines that include making high-tech knee and hip implants, had been in the midst of a turnaround plan and recently faced calls from its biggest investors to break up the business. Smith & Nephew said it had made 'solid progress fixing the foundations' and it was expecting a 'step-up in returns in 2025'. Its share price closed 6.1% higher. Unilever announced its chief executive Hein Schumacher will leave next month after less than two years in the top job, a decision it said had been made 'by mutual agreement'. He will be replaced by chief financial officer Fernando Fernandez who had been appointed to the finance position in January 2024. Unilever's share price dipped following the unexpected changeover at the top, and was down 1.3% at close. The biggest risers on the FTSE 100 were Smith & Nephew, up 64p to 1,107.5p, BAE Systems, up 61p to 1,366p, HSBC, up 21.8p to 899.5p, Natwest Group, up 9.6p to 453.3p, and GSK, up 31p to 1,483.5p. The biggest fallers on the FTSE 100 were Polar Capital Technology Trust, down 15p to 336p, Rio Tinto, down 167p to 4,840p, Endeavour Mining, down 55p to 1,619p, Scottish Mortgage Investment Trust, down 34.5p to 1,039.5p, and Ashtead, down 147p to 4,689p.
